SK Biopharmaceuticals, fresh off an FDA nod, preps for $850M IPO in January: report

25th November 2019 Uncategorised 0

Right on the heels of an FDA approval for seizure med Xcopri, South Korea’s SK Biopharmaceuticals is reportedly planning an initial public offering to raise about $850 million. The company plans to list shares in January and has chosen Citigroup and NH Investment & Securities as advisors for the process, the Financial Times reports.

More: SK Biopharmaceuticals, fresh off an FDA nod, preps for 0M IPO in January: report
Source: fierce